Suppr超能文献

东亚草药治疗非小细胞肺癌脑转移的疗效和安全性:系统评价和荟萃分析方案以确定特定草药。

Efficacy and Safety of East Asian Herbal Medicine for Brain Metastases in Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis Protocol to Identify Specific Herbs.

机构信息

Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

Beijing University of Chinese Medicine, Beijing, China.

出版信息

Integr Cancer Ther. 2023 Jan-Dec;22:15347354221150001. doi: 10.1177/15347354221150001.

Abstract

INTRODUCTION

Brain metastasis (BM) is a significant risk factor for survival and prognosis in non-small cell lung cancer (NSCLC). While surgical resection and radiotherapy are the primary treatment modalities, the overall prognosis in NSCLC patients with BM remains poor, and all therapies lead to adverse events. East Asian herbal medicine (EAHM) has broad prospects as an adjuvant treatment, but its efficacy and safety remain controversial. We propose to conduct a systematic review and meta-analysis to summarize the clinical efficacy and safety of EAHM for the treatment of NSCLC with BMs and to identify specific herbs that can improve the prognosis.

METHODS

The PubMed, EMBASE, CENTRAL, Web of Science, CBM, CNKI, Wanfang, VIP, Evidence Reports on Kampo Treatment, ICHUSHI, and Oriental Medicine Advanced Searching Integrated System databases will be searched from their inception to October 2022. Randomized controlled trials will be included. Two authors will evaluate the eligibility and quality of the included trials. The methodological quality will be assessed using the RoB 2 tool, and Stata 16 will be used for data synthesis. Publication bias will be assessed using funnel plots and Egger tests. The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) system will evaluate the quality of the synthesized evidence. Further sensitivity analyses will be performed to determine the efficacies of specific herbs in EAHM.

DISCUSSION

Given there are currently no systematic reviews and meta-analyses of the efficacy of EAHM as a treatment for NSCLC with BMs, a compilation and analysis of the available high-quality clinical research evidence are essential. The results will help establish guidelines for the application of specific herbs as a complementary alternative therapy for BMs in NSCLC. The findings will be published in a peer-reviewed journal.

PROSPERO REGISTRATION NUMBER

CRD42022300527.

摘要

简介

脑转移(BM)是非小细胞肺癌(NSCLC)患者生存和预后的重要危险因素。虽然手术切除和放疗是主要的治疗方式,但 NSCLC 伴 BM 患者的总体预后仍然较差,所有治疗方法都会导致不良事件。东亚草药(EAHM)作为辅助治疗具有广阔的前景,但疗效和安全性仍存在争议。我们建议进行系统评价和荟萃分析,总结 EAHM 治疗 NSCLC 伴 BM 的临床疗效和安全性,并确定可以改善预后的具体草药。

方法

从建库至 2022 年 10 月,我们将检索 PubMed、EMBASE、CENTRAL、Web of Science、CBM、CNKI、Wanfang、VIP、Kampo Treatment 证据报告、ICHUSHI 和 Oriental Medicine Advanced Searching Integrated System 数据库。我们将纳入随机对照试验。两名作者将评估纳入试验的合格性和质量。方法学质量将使用 RoB 2 工具进行评估,数据综合将使用 Stata 16 进行。使用漏斗图和 Egger 检验评估发表偏倚。使用 GRADE(推荐评估、制定与评价)系统评估综合证据的质量。进一步进行敏感性分析,以确定 EAHM 中特定草药的疗效。

讨论

鉴于目前尚无 EAHM 治疗 NSCLC 伴 BM 的疗效系统评价和荟萃分析,因此必须对现有的高质量临床研究证据进行综合分析。研究结果将有助于为 NSCLC 伴 BM 患者应用特定草药作为补充替代疗法制定指南。研究结果将发表在同行评议的期刊上。

注册编号

CRD42022300527。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a28/9893100/afaee5bedc9e/10.1177_15347354221150001-fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验